This trial is designed to study the safety of giving the drug pembrolizumab to people who have had a stem cell transplant to treat their cancer. Pembrolizumab will be given at a fixed dose of 200 mg IV (into a vein) every 3 weeks. Up to 26 patients will be enrolled in this trial.
1 Primary · 3 Secondary · Reporting Duration: From start date of therapy to the date of death from any cause, whichever may come first, assessed up to 100 months
Experimental Treatment
26 Total Participants · 1 Treatment Group
Primary Treatment: Pembrolizumab · No Placebo Group · Phase < 1
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: